CJC-1295 DAC vs no DAC: what is the difference?

CJC-1295 with DAC and CJC-1295 no DAC are often presented as two versions of the same research peptide. They act on the same general pathway, but they are not interchangeable.

The central difference is duration. CJC-1295 with DAC is designed to bind to albumin and remain active for several days. The product commonly sold as CJC-1295 no DAC lacks this albumin-binding component and is used to study a shorter, more pulse-like GHRH signal.

There is also an important naming detail: in scientific literature, CJC-1295 usually refers to the DAC-containing compound. “CJC-1295 no DAC” is the familiar commercial name for the shorter-acting peptide more precisely known as Modified GRF (1-29).

CJC-1295 DAC vs No DAC at a glance

Feature	CJC-1295 with DAC	CJC-1295 no DAC
More precise name	CJC-1295 / DAC:GRF	Modified GRF (1-29)
Peptide family	GHRH analogue	GHRH analogue
Primary pathway	GHRH receptor → GH → IGF-1 signalling	GHRH receptor → GH → IGF-1 signalling
Albumin binding	Yes	No
Signal profile	Prolonged exposure	Shorter, pulse-like exposure
Reported human half-life	Approximately 5.8–8.1 days	Far shorter; not established in the same clinical studies
Typical research focus	Sustained GH-axis stimulation	Transient or pulsatile GHRH signalling
LIFE product	CJC-1295 with DAC, 2 mg	CJC-1295 no DAC, 5 mg

In simple terms: DAC is the long-acting option, while no DAC is the short-acting option. Neither is universally better—the appropriate choice depends on the research model.

Explore the compounds: CJC-1295 with DAC · CJC-1295 no DAC

What does DAC mean in CJC-1295?

DAC stands for Drug Affinity Complex. It is the structural addition that enables CJC-1295 to form a stable bond with albumin, a long-lived protein circulating in the blood.

Without this feature, small peptides are generally cleared and broken down relatively quickly. Albumin binding protects the DAC-containing molecule from rapid removal and greatly extends its exposure time.

This is not merely a small change in strength. It changes the compound’s pharmacokinetic profile and therefore the type of research question it can answer.

The original preclinical work identified CJC-1295 as a long-lasting GHRH analogue through this albumin-binding design. In a later study involving healthy adults, its estimated half-life was 5.8 to 8.1 days, with elevated GH and IGF-1 measurements persisting well beyond the initial exposure.

What is CJC-1295 no DAC?

The product widely called CJC-1295 no DAC is a modified 29-amino-acid fragment of growth hormone-releasing hormone. It retains substitutions intended to improve stability compared with native GHRH, but it does not include the albumin-binding DAC extension.

For that reason, it is much shorter acting than CJC-1295 with DAC. Its research profile is commonly described as pulse-like rather than sustained.

The more accurate scientific name is Modified GRF (1-29). Nevertheless, “CJC-1295 no DAC” has become the name most researchers and buyers use when searching for the product, so both terms are useful when comparing compounds.

Do both forms work through the same pathway?

Broadly, yes. Both are GHRH analogues and activate the growth hormone-releasing hormone receptor at the pituitary level. This stimulates endogenous GH release, which can subsequently influence IGF-1 signalling.

The difference is mainly the time profile of receptor stimulation:

CJC-1295 with DAC: prolonged systemic exposure and sustained GH-axis stimulation.
CJC-1295 no DAC: shorter GHRH-receptor stimulation suited to research centred on transient signalling.

It is tempting to reduce this to “constant versus pulsatile GH,” but that is slightly too simplistic. Human research found that physiological GH pulsatility could persist during continuous stimulation with DAC-containing CJC-1295.

DAC extends exposure; it does not necessarily flatten every GH pulse into a completely constant signal.

Which is better: CJC-1295 DAC or no DAC?

Neither form is inherently better. They are designed for different experimental models.

CJC-1295 with DAC may fit research focused on:

Prolonged GHRH-receptor stimulation
Sustained GH and IGF-1 responses
Albumin-binding peptide technology
Longer pharmacokinetic observation windows
Cumulative effects following repeated exposure

CJC-1295 no DAC may fit research focused on:

Shorter-duration GHRH signalling
Transient or pulse-oriented experimental designs
Timing relationships between GHRH and other signalling pathways
Models where prolonged albumin-bound exposure is undesirable
Comparison with other short-acting GH secretagogues

The practical buying decision should therefore follow the intended laboratory protocol—not the assumption that longer action automatically means a stronger or superior compound.

Is CJC-1295 no DAC really CJC-1295?

This is where product terminology and scientific terminology diverge.

Strictly speaking, the name CJC-1295 was assigned to the long-acting, DAC-containing molecule. The short-acting tetra-substituted GHRH fragment without the DAC extension is Modified GRF (1-29).

However, “CJC-1295 no DAC” is now the established commercial search term. Reputable product information should make the relationship clear rather than ignoring the naming issue:

CJC-1295 with DAC is the original long-acting, albumin-binding compound.
CJC-1295 no DAC is the commonly used market name for Modified GRF (1-29).

This distinction matters when reading studies. Human pharmacokinetic results for CJC-1295 with DAC should not automatically be applied to the no-DAC product.

CJC-1295 versus Ipamorelin: are they the same type of peptide?

No. Although both appear in growth-hormone research, they activate different receptors.

CJC-1295 and Modified GRF (1-29) are GHRH-receptor agonists. Ipamorelin is a ghrelin-receptor agonist, also described as a growth hormone secretagogue receptor agonist.

Researchers may investigate the pathways separately or examine how GHRH and ghrelin-receptor signals interact, but one compound is not simply a substitute for the other.

For a broader explanation, see our Growth Hormone Peptides Research Guide or explore Ipamorelin.

Choosing between the two LIFE research products

LIFE supplies both formats for laboratory and analytical research.

CJC-1295 with DAC

The long-acting format for research involving albumin binding and prolonged GHRH-axis signalling.

View CJC-1295 with DAC

CJC-1295 no DAC — 5 mg

The short-acting Modified GRF (1-29) format for research involving transient or pulse-oriented GHRH signalling.

View CJC-1295 no DAC

Both products are supplied as lyophilised research material with batch documentation. They are intended strictly for laboratory research and analytical use—not for human or veterinary use.

Frequently asked questions

What is the main difference between CJC-1295 DAC and no DAC?

The primary difference is albumin binding and duration. DAC-containing CJC-1295 binds to albumin and has a reported half-life of several days. CJC-1295 no DAC lacks that binding component and produces a much shorter exposure profile.

What does “no DAC” mean?

It means the peptide does not contain the Drug Affinity Complex used for albumin binding. Removing that feature changes it from a long-acting research compound into a shorter-acting GHRH analogue.

Is CJC-1295 no DAC the same as Modified GRF (1-29)?

In the research-peptide market, these names normally refer to the same short-acting compound. Modified GRF (1-29) is the more chemically accurate term; CJC-1295 no DAC is the more commonly searched commercial name.

Does CJC-1295 with DAC produce only a constant GH signal?

Not exactly. DAC creates prolonged exposure, but published human research found that pulsatile GH secretion persisted during continuous CJC-1295 stimulation. “Long acting” is more accurate than describing the response as completely flat or constant.

Is CJC-1295 no DAC stronger than CJC-1295 with DAC?

The two cannot be ranked meaningfully by vial amount or a simple “stronger” label. Their most important difference is the duration and pattern of exposure. The relevant choice depends on the experimental design.

Can research findings from CJC-1295 with DAC be applied to no DAC?

Not automatically. They share a GHRH-related core pathway, but their pharmacokinetics are very different. Studies should be checked carefully to establish which molecule was actually investigated.

Summary

CJC-1295 with DAC and CJC-1295 no DAC act through the GHRH pathway, but their exposure profiles are fundamentally different.

With DAC: albumin binding, multi-day half-life and prolonged GH/IGF-1 signalling.
No DAC: no albumin binding, shorter exposure and pulse-oriented GHRH research.

The phrase “CJC-1295 no DAC” is commercially familiar, while Modified GRF (1-29) is scientifically more precise. For buyers comparing the two, the deciding question is not which peptide is generally better—it is whether the research model requires sustained or short-duration signalling.

Compare the available formats: CJC-1295 with DAC · CJC-1295 no DAC

Browse all compounds in the Growth hormone secretagogues category.

References

Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058.
Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792–4797.